HOUSTON, TX / ACCESSWIRE / April 1, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company…
ELI-002 2P clinical immunogenicity data were accepted for a poster presentation at the AACR Annual Meeting 2024ELI-007 and ELI-008 preclinical…
Launch of OLPRUVA® underway Topline results from KP1077 phase 2 study demonstrate clinically meaningful benefits for key IH symptoms Q4…
Funding from new investors, including RA Capital Management, Armistice Capital, Special Situations Funds and Soleus Capital $50 million financing upfront…
Collaborative Study involving the VA and UCSD achieved statistically significant decrease in PCS and PTSD symptoms versus control group The…
On track for topline data from CAN-2409 phase 3 in localized intermediate/high risk prostate cancer, expected in Q4 2024Results from…
Providence, RI, March 28, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the development…
Data Published in Leading Peer-Reviewed Publication, Journal of Clinical MedicineJERUSALEM and BURLINGTON, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- BrainsWay…
TORONTO, ON / ACCESSWIRE / March 27, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical…
SPARKS, NV / ACCESSWIRE / March 27, 2024 / Ludwig Enterprises, Inc, (OTC PINK:LUDG): A US-based biotechnology company is pleased…